Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2015, Article ID 284360, 15 pages
http://dx.doi.org/10.1155/2015/284360
Research Article

Monte Carlo Calculation of Radioimmunotherapy with 90Y-, 177Lu-, 131I-, 124I-, and 188Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts

1Research Centre for the Physics of Matter and Radiation (PMR), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium
2NAmur Research Institute for LIfe Sciences (NARILIS), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium
3Pharmacology and Therapeutics Unit (FATH), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCL), 53 Avenue Mounier, 1200 Brussels, Belgium
4Biomedical Magnetic Resonance Group (REMA), Louvain Drug Research Institute, Université Catholique de Louvain (UCL), 73 Avenue Mounier, 1200 Brussels, Belgium
5Namur Medicine and Drug Innovation Center (NAMEDIC), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium
6Unité de Recherche en Biologie Cellulaire (URBC), University of Namur, 61 Rue de Bruxelles, 5000 Namur, Belgium
7Centre for Molecular Imaging, Radiotherapy and Oncology (MIRO), Institute of Experimental and Clinical Research (IREC), Université Catholique de Louvain (UCL), 1 Dr. G. Therasse, 5530 Yvoir, Belgium

Received 8 July 2014; Accepted 27 October 2014

Academic Editor: Mario Bernal

Copyright © 2015 S. Lucas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. L. J. Dearling and R. B. Pedley, “Technological advances in radioimmunotherapy,” Clinical Oncology, vol. 19, no. 6, pp. 457–469, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Gruaz-Guyon, O. Raguin, and J. Barbet, “Recent advances in pretargeted radioimmunotherapy,” Current Medicinal Chemistry, vol. 12, no. 3, pp. 319–338, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. W. A. Bethge and B. M. Sandmaier, “Targeted cancer therapy using radiolabeled monoclonal antibodies,” Technology in Cancer Research & Treatment, vol. 4, no. 4, pp. 393–405, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. V. Govindan, G. L. Griffiths, H. J. Hansen, I. D. Horak, and D. M. Goldenberg, “Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies,” Technology in Cancer Research & Treatment, vol. 4, no. 4, pp. 375–391, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. W. Brechbiel, O. A. Gansow, R. W. Atcher et al., “Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies,” Inorganic Chemistry, vol. 25, no. 16, pp. 2772–2781, 1986. View at Google Scholar · View at Scopus
  6. T. K. Nikula, M. Bocchia, M. J. Curcio et al., “Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity,” Molecular Immunology, vol. 32, no. 12, pp. 865–872, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Bouchat, N. Moreau, V. Valembois et al., “On the use of radioisotopes to study the possible synthesis by magnetron sputtering of bimetallic nanoparticles,” Surface and Coatings Technology, vol. 205, no. 21-22, pp. 4934–4940, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. K. V. Katti, R. Kannan, K. Katti et al., “Hybrid gold nanoparticles in molecular imaging and radiotherapy,” Czechoslovak Journal of Physics, vol. 56, no. 4, pp. D23–D34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Wu, J. Wang, Z. Wang, D. R. Fisher, and Y. Lin, “Apoferritin-templated yttrium phosphate nanoparticle conjugates for radioimmunotherapy of cancers,” Journal of Nanoscience and Nanotechnology, vol. 8, no. 5, pp. 2316–2322, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Gref, M. Lück, P. Quellec et al., “‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption,” Colloids and Surfaces B: Biointerfaces, vol. 18, no. 3-4, pp. 301–313, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. D. E. Owens III and N. A. Peppas, “Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles,” International Journal of Pharmaceutics, vol. 307, no. 1, pp. 93–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Karmani, D. Labar, V. Valembois et al., “Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice,” Contrast Media & Molecular Imaging, vol. 8, no. 5, pp. 402–408, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Marega, L. Karmani, L. Flamant et al., “Antibody-functionalized polymer-coated gold nanoparticles targeting cancer cells: an in vitro and in vivo study,” Journal of Materials Chemistry, vol. 22, no. 39, pp. 21305–21312, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Bouchat, V. E. Nuttens, S. Lucas et al., “Radioimmunotherapy with radioactive nanoparticles: first results of dosimetry for vascularized and necrosed solid tumors,” Medical Physics, vol. 34, no. 11, pp. 4504–4513, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. V. Bouchat, V. E. Nuttens, C. Michiels et al., “Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area,” Medical Physics, vol. 37, no. 4, pp. 1826–1839, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Nagata, K. Takayama, Y. Matsuo et al., “Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame,” International Journal of Radiation Oncology Biology Physics, vol. 63, no. 5, pp. 1427–1431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Nyman, K.-A. Johansson, and U. Hultén, “Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—mature results for medically inoperable patients,” Lung Cancer, vol. 51, no. 1, pp. 97–103, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. F. J. Lagerwaard, C. J. Haasbeek, B. J. Slotman, and S. Senan, “Clinical results and toxicity after 4-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer (NSCLC): B5-04,” Journal of Thoracic Oncology, vol. 2, no. 8, p. S348, 2007. View at Publisher · View at Google Scholar
  19. R. Timmerman, R. McGarry, C. Yiannoutsos et al., “Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer,” Journal of Clinical Oncology, vol. 24, no. 30, pp. 4833–4839, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Glatting, M. Bardies, and M. Lassmann, “Treatment planning in molecular radiotherapy,” Zeitschrift für Medizinische Physik, vol. 23, no. 4, pp. 262–269, 2013. View at Publisher · View at Google Scholar
  21. G. A. Wiseman, C. A. White, R. B. Sparks et al., “Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma,” Critical Reviews in Oncology/Hematology, vol. 39, no. 1-2, pp. 181–194, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. J.-P. Pouget, I. Navarro-Teulon, M. Bardiès et al., “Clinical radioimmunotherapy—the role of radiobiology,” Nature Reviews Clinical Oncology, vol. 8, no. 12, pp. 720–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Lauter, A. Strumpf, U. Platzbecker et al., “188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation: Research paper,” British Journal of Haematology, vol. 148, no. 6, pp. 910–917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ringhoffer, N. Blumstein, B. Neumaier et al., “188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study,” British Journal of Haematology, vol. 130, no. 4, pp. 604–613, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. R. D. Alvarez, E. E. Partridge, M. B. Khazaeli et al., “Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study,” Gynecologic Oncology, vol. 65, no. 1, pp. 94–101, 1997. View at Publisher · View at Google Scholar · View at Scopus
  26. R. F. Meredith, E. E. Partridge, R. D. Alvarez et al., “Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49,” The Journal of Nuclear Medicine, vol. 37, no. 9, pp. 1491–1496, 1996. View at Google Scholar · View at Scopus
  27. S. Vallabhajosula, S. J. Goldsmith, K. A. Hamacher et al., “Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen,” Journal of Nuclear Medicine, vol. 46, no. 5, pp. 850–858, 2005. View at Google Scholar · View at Scopus
  28. R. Chaturvedi, J. Heimburg, J. Yan et al., “Tumor immunolocalization using 124I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen,” Applied Radiation and Isotopes, vol. 66, no. 3, pp. 278–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Verel, G. W. M. Visser, and G. A. van Dongen, “The promise of immuno-PET in radioimmunotherapy,” Journal of Nuclear Medicine, vol. 46, supplement 1, pp. 164S–171S, 2005. View at Google Scholar · View at Scopus
  30. K. S. Pentlow, M. C. Graham, R. M. Lambrecht et al., “Quantitative imaging of iodine-124 with PET,” Journal of Nuclear Medicine, vol. 37, no. 9, pp. 1557–1562, 1996. View at Google Scholar · View at Scopus
  31. V. E. Nuttens, A.-C. Wéra, V. Bouchat, and S. Lucas, “Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles,” Applied Radiation and Isotopes, vol. 66, no. 2, pp. 168–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. R. W. Howell, D. V. Rao, and K. S. R. Sastry, “Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors,” Medical Physics, vol. 16, no. 1, pp. 66–74, 1989. View at Publisher · View at Google Scholar · View at Scopus
  33. D. J. Macey and R. F. Meredith, “A strategy to reduce red marrow dose for intraperitoneal radioimmunotherapy,” Clinical Cancer Research, vol. 5, supplement 10, pp. 3044s–3047s, 1999. View at Google Scholar · View at Scopus
  34. R. K. Bodey, P. M. Evans, and G. D. Flux, “Application of the linear-quadratic model to combined modality radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 59, no. 1, pp. 228–241, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Seppenwoolde, J. V. Lebesque, K. de Jaeger et al., “Comparing different NTCP models that predict the incidence of radiation pneumonitis,” International Journal of Radiation Oncology, Biology, Physics, vol. 55, no. 3, pp. 724–735, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. P. Källman, A. Ågren, and A. Brahme, “Tumour and normal tissue responses to fractionated non-uniform dose delivery,” International Journal of Radiation Biology, vol. 62, no. 2, pp. 249–262, 1992. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Burman, G. J. Kutcher, B. Emami, and M. Goitein, “Fitting of normal tissue tolerance data to an analytic function,” International Journal of Radiation Oncology Biology Physics, vol. 21, no. 1, pp. 123–135, 1991. View at Google Scholar · View at Scopus
  38. R. W. Howell, S. M. Goddu, and D. V. Rao, “Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides,” Journal of Nuclear Medicine, vol. 35, no. 11, pp. 1861–1869, 1994. View at Google Scholar · View at Scopus
  39. M. Mehta, R. Scrimger, R. Mackie, B. Paliwal, R. Chappell, and J. Fowler, “A new approach to dose escalation in non-small-cell lung cancer,” International Journal of Radiation Oncology, Biology, Physics, vol. 49, no. 1, pp. 23–33, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Ruggieri, “Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia,” Physics in Medicine and Biology, vol. 49, no. 20, pp. 4811–4823, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Baechler, R. F. Hobbs, A. R. Prideaux, R. L. Wahl, and G. Sgouros, “Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry,” Medical Physics, vol. 35, no. 3, pp. 1123–1134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Guerrero and X. A. Li, “Halftime for repair of sublethal damage in normal bladder and rectum: an analysis of clinical data from cervix brachytherapy,” Physics in Medicine and Biology, vol. 51, no. 16, pp. 4063–4071, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Dubray, M. Henry-Amar, J. H. Meerwaldt et al., “Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation,” Radiotherapy and Oncology, vol. 36, no. 3, pp. 211–217, 1995. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Webb and A. E. Nahum, “A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density,” Physics in Medicine and Biology, vol. 38, no. 6, pp. 653–666, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. K.-R. Trott, “Chemoradiotherapy interactions and lung toxicity,” Annals of Oncology, vol. 10, supplement 5, pp. S77–S81, 1999. View at Google Scholar · View at Scopus